Market Assessment, Antipsychotics Access and Reimbursement China 2016 Report

Schizophrenia and major depressive disorder (MDD) are disabling psychiatric conditions that are linked to a heavy economic and disease burden on society and patients as well as their caregivers. Antipsychotics (older typical or newer atypical antipsychotics) are the standard of care for schizophrenia, and they are also used among treatment-resistant MDD patients. In an overgenericized market of well-established, mostly reimbursed key agents, psychiatrists may be reluctant to switch to newer and more expensive treatment options. However, high unmet need remains for therapies with demonstrated efficacy for both conditions. In this Access & Reimbursement analysis, we discuss the current access landscape for antipsychotics in China, with a focus on atypical antipsychotics’ use in schizophrenia and MDD. In addition, we analyze the future uptake of emerging therapies (e.g., Sumitomo Dainippon’s Latuda) and pinpoint the levers and roadblocks to their success.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Antipsychotics | Access and Reimbursement | China | 2016

Related Market Assessment Reports

Non-Small-Cell Lung Cancer – Geographic Focus: China – Non-Small-Cell Lung Cancer – China In-Depth (China)

Asthma – Geographic Focus: China – Asthma – China In-Depth (China)

Squamous Cell Carcinoma Of The Head And Neck – China In-Depth – Squamous Cell Carcinoma Of The Head And Neck – China In-Depth (China)

GLP-1 Receptor Agonists – China In-Depth – GLP-1 Receptor Agonists – China In-Depth – China

Parkinson’s Disease – China In Depth – Parkinson’s Disease – China In-Depth (China)